SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-085991
Filing Date
2021-06-28
Accepted
2021-06-28 08:00:21
Documents
12
Period of Report
2021-06-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2120479d1_8k.htm   iXBRL 8-K 23685
  Complete submission text file 0001104659-21-085991.txt   199379

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ruby-20210622.xsd EX-101.SCH 3188
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20210622_lab.xml EX-101.LAB 34593
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20210622_pre.xml EX-101.PRE 22712
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2120479d1_8k_htm.xml XML 3721
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 211049989
SIC: 2836 Biological Products, (No Diagnostic Substances)